1245646-51-8

Basic information

• Product Name: (1R,5S)-tert-butyl 3-(((trifluoromethyl)sulfonyl)oxy)-8-azabicyclo[3.2.1 ]oct-2-ene-8-carboxylate
• CAS NO: 1245646-51-8
• Molecular Weight: 357.351
• Mol File: 1245646-51-8.mol

Chemical Properties

• CAS DataBase Reference: (1R,5S)-tert-butyl 3-(((trifluoromethyl)sulfonyl)oxy)-8-azabicyclo[3.2.1 ]oct-2-ene-8-carboxylate(CAS DataBase Reference)
• NIST Chemistry Reference: (1R,5S)-tert-butyl 3-(((trifluoromethyl)sulfonyl)oxy)-8-azabicyclo[3.2.1 ]oct-2-ene-8-carboxylate(1245646-51-8)
• EPA Substance Registry System: (1R,5S)-tert-butyl 3-(((trifluoromethyl)sulfonyl)oxy)-8-azabicyclo[3.2.1 ]oct-2-ene-8-carboxylate(1245646-51-8)

Safety Data

• Hazardous Substances Data: 1245646-51-8(Hazardous Substances Data)

Usage

Uses

Used in Pharmaceutical Research:
(1R,5S)-tert-butyl 3-(((trifluoromethyl)sulfonyl)oxy)-8-azabicyclo[3.2.1]oct-2-ene-8-carboxylate is used as a research compound for the development of new drugs, leveraging its unique molecular structure to explore its potential therapeutic properties and applications in medicine.
Used in Organic Synthesis:
In the field of organic synthesis, (1R,5S)-tert-butyl 3-(((trifluoromethyl)sulfonyl)oxy)-8-azabicyclo[3.2.1]oct-2-ene-8-carboxylate serves as a building block or intermediate in the creation of more complex chemical structures, contributing to the advancement of chemical science and the discovery of novel materials.

Upstream product

• 37595-74-7 N,N-phenylbistrifluoromethane-sulfonimide 
• 185099-67-6 Boc-tropinone 
• 145100-51-2 N-(5-chloropyridin-2-yl)-1,1,1-trifluoro-N-[(trifluoromethyl)sulphonyl]methanesulphonamide 
• 5632-84-8 8-azabicyclo[3.2.1]octan-3-one 
• 185099-67-6 N-Boc-nortropinone 
• 358-23-6 trifluoromethylsulfonic anhydride 
• 24424-99-5 di-tert-butyl dicarbonate 
• 28957-72-4 N-benzylnortropinone 
• 542-05-2 acetonedicarboxylic acid 
• 25602-68-0 3-oxo-8-azabicyclo[3.2.1]octane hydrochloride 
• 532-24-1 tropinone 
• 5632-84-8 nortropinone 

Downstream Products

• 900503-08-4 3-(4,4,5,5-tetramethyl[1,3,2]dioxaborolan-2-yl)-8-azabicyclo[3.2.1]oct-2-ene-8-carboxylic acid tert-butyl ester 
• 1314641-64-9 3-{2-fluoro-5-[(2,2,2-trifluoro-acetylamino)-methyl]-phenyl}-8-aza-bicyclo[3.2.1]octane-8-carboxylic acid tert-butyl ester 
• 1314641-65-0 N-[3-(8-aza-bicyclo[3.2.1]oct-3-yl)-4-fluoro-benzyl]-2,2,2-trifluoro-acetamide hydrochloride 
• 1314641-69-4 N-{3-[8-(4-bromo-3-methyl-5-propoxy-thiophene-2-carbonyl)-8-azabicyclo[3.2.1]oct-3-yl]-4-fluoro-benzyl}-2,2,2-trifluoro-acetamide 
• 1314641-61-6 [3-(5-aminomethyl-2-fluoro-phenyl)-8-aza-bicyclo[3.2.1]oct-8-yl]-(4-bromo-3-methyl-5-propoxy-thiophen-2-yl)-methanone hydrochloride 
• 949901-52-4 3-endo-(8-aza-bicyclo[3.2.1]oct-3-yl)-phenol 
• 1319255-25-8 tert-butyl 3-(7-(bis((2-(trimethylsilyl)ethoxy)methyl)amino)-3-(6-phenylpyridin-3-yl)pyrazolo[1,5-a]pyrimidin-5-yl)-8-azabicyclo[3.2.1]octane-8-carboxylate 
• 1319255-26-9 tert-butyl 3-(7-(bis((2-(trimethylsilyl)ethoxy)methyl)amino)-6-bromo-3-(6-phenylpyridin-3-yl)pyrazolo[1,5-a]pyrimidin-5-yl)-8-azabicyclo[3.2.1]octane-8-carboxylate 
• 1319255-27-0 tert-butyl 3-(7-(bis((2-(trimethylsilyl)ethoxy)methyl)amino)-6-(1-ethoxyvinyl)-3-(6-phenylpyridin-3-yl)pyrazolo[1,5-a]pyrimidin-5-yl)-8-azabicyclo[3.2.1]octane-8-carboxylate 
• 1421271-46-6 5-((1R,3s,5S)-8-azabicyclo[3.2.1]octan-3-yl)-3-(6-phenylpyridin-3-yl)-8-pyrazolo[1,5-a]pyrrolo[3,2-e]pyrimidine 
• 1421271-38-6 C₂₉H₂₅N₉O 
• 900503-43-7 3-(8-tert-butoxycarbonyl-8-azabicyclo[3.2.1]oct-2-en-3-yl)-1H-indole-2-carboxylic acid ethyl ester 
• 900503-42-6 3-pyridin-2-yl-8-azabicyclo[3.2.1]oct-2-ene-8-carboxylic acid tert-butyl ester 
• 179022-43-6 methyl 8-(1-(2-chloro-6-(trifluoromethyl)benzoyl)-1H-pyrazolo[4,3-b]pyridin-3-yl)-8-aza-bicyclo[3.2.1]octane-3-carboxylate 

Relevant articles and documents

Carbonyl 1,2-transposition through triflate-mediated a-amination

To date, it remains challenging to selectively migrate a carbonyl oxygen within a given molecular scaffold, especially to an adjacent carbon. In this work, we describe a simple one- or two-pot protocol that transposes a ketone to the vicinal carbon. This approach first converts the ketone to the corresponding alkenyl triflate, which can then undergo the palladium- and norbornene-catalyzed regioselective a-amination and ipso-hydrogenation enabled by a bifunctional hydrogen and nitrogen donor. The resulting "transposed enamine" intermediate can subsequently be hydrolyzed to produce the 1,2-carbonyl-migrated product. This method allows rapid access to unusual bioactive analogs through late-stage functionalization.

WEE1 inhibitors as well as preparation and application thereof

The invention relates to WEE1 inhibitors as well as preparation and application thereof. The present invention relates to compounds of formula (I), or pharmaceutically acceptable salts, solvates, polymorphs or isomers thereof, and their use in the preparation of medicaments for the treatment of diseases associated with WEE1 activity.

Compound and application thereof

The invention provides a novel compound. The novel compound has certain inhibitory activity for indoleamine 2,3-dioxygenase (IDO) which is oxido-reductase, and accordingly the novel compound can be used for treating diseases related to the indoleamine 2,3-dioxygenase and can be applied to cancer and immunity related diseases.

HPK1 inhibitor and application thereof

The invention belongs to the technical field of medicines, and specifically relates to an HPK1 inhibitor compound as shown in a formula (I) which is described in the specification or a pharmaceutically-acceptable salt and a stereoisomer of the HPK1 inhibi

OXALAMIDES AS MODULATORS OF INDOLEAMINE 2,3-DIOXYGENASE

The present invention relates to novel compounds which act as modulators of indoleamine 2,3-dioxygenase (IDOl) and to the use of said compounds in the prophylaxis and/or treatment of diseases or conditions mediated by indoleamine 2,3-dioxygenase. The inve

TETRAHYDROPYRIDO[4,3-D]PYRIMIDINE INHIBITORS OF ATR KINASE

The present invention relates to tetrahydropyrido[4,3-d]pyrimidine based compounds and methods which may be useful as inhibitors of ATR kinase for the treatment or prevention of cancer.

Discovery of N-substituted-endo-3-(8-aza-bicyclo[3.2.1]oct-3-yl)-phenol and -phenyl carboxamide series of μ-opioid receptor antagonists

Gastrointestinal dysfunction as a consequence of the use of opioid analgesics is of significant clinical concern. First generation drugs to treat these opioid-induced side-effects were limited by their negative impact on opioid receptor agonist-induced analgesia. Second generation therapies target a localized, peripherally-restricted, non-CNS penetrant drug distribution of opioid receptor antagonists. Herein we describe the discovery of the N-substituted-endo-3-(8-aza-bicyclo[3.2.1]oct-3-yl)-phenol and -phenyl carboxamide series of μ-opioid receptor antagonists. This report highlights the discovery of the key μ-opioid receptor antagonist pharmacophore and the optimization of in vitro metabolic stability through the application of a phenol bioisostere. The compounds 27a and 31a with the most attractive in vitro profile, formed the basis for the application of Theravance Biopharma's multivalent approach to drug discovery to afford the clinical compound axelopran (TD-1211), targeted for the treatment of opioid-induced constipation.

Tyrosine Kinase Inhibitor And Uses Thereof

Disclosed is a compound of Formula (I) or a pharmaceutically acceptable salt, ester, or solvate thereof, or their stereoisomers, which can be used as tyrosine kinase inhibitor. Also disclosed is a method for preparing the compound, a pharmaceutical composition and a kit comprising the compound, and uses of the compound. The compound can be used as tyrosine kinase inhibitor, or can be used to reduce or inhibit activity of EGFR or mutant thereof, such as EGFR mutant comprising T790M mutation, in a cell, or to treat and/or prevent a disease associated with overactivity of EGFR, such as cancer.

Small Molecule Antagonists of the Nuclear Androgen Receptor for the Treatment of Castration-Resistant Prostate Cancer

After a high-throughput screening campaign identified thioether 1 as an antagonist of the nuclear androgen receptor, a zone model was developed for structure-activity relationship (SAR) purposes and analogues were synthesized and evaluated in a cell-based luciferase assay. A novel thioether isostere, cyclopropane (1S,2R)-27, showed the desired increased potency and structural properties (stereospecific SAR response, absence of a readily oxidized sulfur atom, low molecular weight, reduced number of flexible bonds and polar surface area, and drug-likeness score) in the prostate-specific antigen luciferase assay in C4-2-PSA-rl cells to qualify as a new lead structure for prostate cancer drug development.

SUBSTITUTED PYRAZOLE COMPOUNDS AS SERINE PROTEASE INHIBITORS

There are provided inter alia multisubstituted aromatic compounds useful for the inhibition of thrombin and/or kallikrein, which compounds include substituted pyrazolyl. There are additionally provided pharmaceutical compositions. There are additionally provided methods of treating and preventing certain diseases or disorders, which diseases or disorders are amenable to treatment or prevention by the inhibition of thrombin and/or kallikrein.